J. M. P. A. van den Reek

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio<scp>CAPTURE</scp>network

J. M. P. A. van den Reek, Jeffrey Zweegers, Wietske Kievit et al. · British Journal of Dermatology · 2014 · 97 citations

An increased risk of non‐melanoma skin cancer during <scp>TNF</scp>‐inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease‐related factors

P.P.M. van Lümig, S.P. Menting, J. M. P. A. van den Reek et al. · Journal of the European Academy of Dermatology and Venereology · 2014 · 66 citations

Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry

Jeffrey Zweegers, J.M.M. Groenewoud, J. M. P. A. van den Reek et al. · British Journal of Dermatology · 2016 · 53 citations

Determinants of drug survival for etanercept in a long‐term daily practice cohort of patients with psoriasis

J. M. P. A. van den Reek, P.P.M. van Lümig, R.J.B. Driessen et al. · British Journal of Dermatology · 2013 · 41 citations

Increased incidence of squamous cell carcinoma of the skin after long‐term treatment with azathioprine in patients with auto‐immune inflammatory rheumatic diseases

J. M. P. A. van den Reek, P.P.M. van Lümig, M. Janssen et al. · Journal of the European Academy of Dermatology and Venereology · 2012 · 39 citations